Navigation Links
Varian, Inc. Reports Fourth Quarter 2009 Results
Date:11/4/2009

luding $3,018 related to the impairment of a private company equity investment. (13) $44,007 on an adjusted basis excluding the tax impact of the adjustments described in items (7) - (9) and (12) above. (14) $78,689 and $2.62 per share, respectively, on an adjusted basis excluding the adjustments (net of related tax effects) described in items (7) - (10) and (12) above. 

                     VARIAN, INC. AND SUBSIDIARY COMPANIES

                 UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET
                    (In thousands, except par value amounts)

                                                October 2,      October 3,
                                                   2009            2008
                                                 ---------       ---------
    ASSETS

    Current assets
    Cash and cash equivalents                    $209,348        $103,895
    Accounts receivable, net                      159,958         199,420
    Inventories                                   136,704         161,039
    Deferred taxes                                 38,349          32,287
    Prepaid expenses and other current assets      15,488          15,663
                                                 ---------       ---------
    Total current assets                          559,847         512,304
    Property, plant and equipment, net            114,363         110,343
    Goodwill                                      216,223         218,208
    Intangible assets, net                         28,334          36,972
    Other assets                                   25,420          24,089
                                                 ---------       ---------
    Total assets                                 $944,187        $901,916
                                                 =========       =========

    LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities
    Current portion of lo
'/>"/>
SOURCE  Varian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 

Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Cancer patients in Finland have gained access ... RapidArc® radiotherapy technology from Varian Medical Systems (NYSE: ... radiotherapy clinic in the Nordic region. Clinicians at ... and precise form of radiotherapy to treat patients ... abdomen and prostate. ,, RapidArc, which enables clinicians ...
(Date:12/14/2009)... Dec. 14 According to Millennium Research ... market intelligence, increased use of safety devices for ... be a key driver of the enteral feeding ... MRG,s new US and European Markets for ... the giving set segment will experience the greatest ...
(Date:12/14/2009)... Dec. 14 ... a leading provider of tools and services for ... that it has completed the sale of Xenogen ... pre-clinical CRO services, to Taconic Farms, Inc. for ... Caliper as part of Caliper,s acquisition of Xenogen ...
Breaking Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 2Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 4Ionian Technologies Inc Receives Additional Funding from the Bill 26amp 3B Melinda Gates Foundation to Develop Point of Care Diagnostic Tests for t 6373 1Ionian Technologies Inc Receives Additional Funding from the Bill 26amp 3B Melinda Gates Foundation to Develop Point of Care Diagnostic Tests for t 6373 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles 6369 1Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles 6369 2Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles 6369 3Covance Enters Into a Biomarker Alliance With Rules Based Medicine Inc 6365 1Covance Enters Into a Biomarker Alliance With Rules Based Medicine Inc 6365 2Covance Enters Into a Biomarker Alliance With Rules Based Medicine Inc 6365 3Covance Enters Into a Biomarker Alliance With Rules Based Medicine Inc 6365 4
... has now been studied in combination with the most ... mg, 20 mg) in patients with mixed dyslipidemiaORLANDO, Fla., ... that Abbott ,s TRILIPIX(R) (fenofibric acid) delayed-release capsules ... study,s primary endpoints. TRILIPIX 135 mg in combination ...
... A new analysis from the,JUPITER study shows that ... venous thromboembolism (VTE) by 43% (p =0.007) compared ... normal cholesterol levels and elevated,high-sensitivity C-reactive protein (hsCRP). ... American College of Cardiology Scientific Sessions (ACC) in,Orlando, ...
Other Medicine Technology:New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 2New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 3New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 4New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management 5CRESTOR(R) Reduced Risk of Blood Clots in the Veins 2CRESTOR(R) Reduced Risk of Blood Clots in the Veins 3CRESTOR(R) Reduced Risk of Blood Clots in the Veins 4
(Date:12/14/2009)... gardening replaced tube watching , , MONDAY, Dec. 14 (HealthDay ... hours of television a week until he enrolled in ... time in half. , During his enforced period of ... not necessarily through strenuous exercise, although he did find ... time was spent reading and working on the computer, ...
(Date:12/14/2009)... Steve Pasierb, President ,, NEW YORK, Dec. ... Monitoring the Future study (MTF) -- the largest survey ... and 12th graders -- underscores that teens, intentional abuse ... be a cause for concern, with an alarming number ... and relatives. ,, Teen Abuse of ...
(Date:12/14/2009)... Krause, an aerospace engineer,for NASA, was giving the ... he,was confident that technology and science could solve ... one thing that science couldn,t solve.,His wife Susan ... machines,would keep her alive for awhile, she would ... 69 and is starting dialysis next month. She ...
(Date:12/14/2009)... team of scientists from the UC San Diego School ... a protein switch that helps prevent liver damage, including ... better understanding of how the protein, TAK1, works could ... disease and cancer. , "TAK1 appears to be ... Brenner, MD, professor of medicine and Dean of the ...
(Date:12/14/2009)... report cites lower rates for meth and smoking, ... Dec. 14 (HealthDay News) -- Fewer teenagers are ... stalled and abuse of prescription drugs remains high, ... said that newer drugs, such as the hallucinogenic ... is intended for treatment of attention-deficit hyperactivity disorder ...
Breaking Medicine News(10 mins):Health News:Cutting TV Time Burns More Calories 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 2Health News:69-Year-Old Grandmother Needing A Lifesaving Kidney Transplant Finds a Miracle on the Internet: a 25-Year-Old Living Altruistic Organ Donor Stranger 3Health News:Scientists uncover protective mechanism against liver cancer 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 2Health News:Marijuana Use No Longer Dropping Among U.S. Teens 3Health News:Marijuana Use No Longer Dropping Among U.S. Teens 4
... a songbird may appear effortless, but his elocutions are ... and maintained throughout adulthood. His tune has virtually crystallized ... motor performance of top athletes and musicians. Yet, subtle ... and humans. Now, scientists think they know why. ...
... Gillings, Bain ... Capital and TPG, ... the formation of a new investor,partnership to support the company,s continued ... and the management team.,Gillings and global private investment firms Bain Capital ...
... MASI ), the inventor of Pulse CO-Oximetry and Read-Through ... is scheduled to,present at the 26th Annual JPMorgan Healthcare ... on Monday, January 7, 2008 at 8:30 a.m. PT.,Joe ... Raad, Executive Vice,President and CFO, will be presenting., ...
... without disease progression, study found , , FRIDAY, Dec ... two drugs, Avastin (bevacizumab) plus interferon, extends the ... report. , "Based on the result of earlier ... bevacizumab as a new drug for treating kidney ...
... Mass., Dec. 21 PLC Systems Inc.,(Amex: PLC ... Mark Certificate,for its RenalGuard System(TM), clearing the way for ... in the European Union. The Company,expects to initiate a ... in Italy, targeting early adoptors who recognize the benefits ...
... of Time" a Valuable Present: Peake, WASHINGTON, Dec. ... the volunteers who remember our nation,s,veterans, especially those hospitalized ... year., "Some of our patients will be unable ... James B. Peake, Secretary of Veterans Affairs. "The,good cheer ...
Other Medicine News:Health News:Songbirds offer clues to highly practiced motor skills in humans 2Health News:Songbirds offer clues to highly practiced motor skills in humans 3Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 2Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 3Health News:Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i 4Health News:Masimo to Present at 26th Annual JPMorgan Healthcare Conference 2Health News:New Combo Treatment Extends Kidney Cancer Survival 2Health News:PLC Systems Receives CE Mark Approval for RenalGuard(TM) 2Health News:PLC Systems Receives CE Mark Approval for RenalGuard(TM) 3Health News:PLC Systems Receives CE Mark Approval for RenalGuard(TM) 4Health News:VA Salutes Volunteers' Spreading Holiday Cheer 2
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Medicine Products: